Last reviewed · How we verify
Metformin Immediate-Release Tablet — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Metformin Immediate-Release Tablet (Metformin Immediate-Release Tablet) — Aspargo Labs, Inc.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Metformin Immediate-Release Tablet TARGET | Metformin Immediate-Release Tablet | Aspargo Labs, Inc | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Metformin Immediate-Release Tablet CI watch — RSS
- Metformin Immediate-Release Tablet CI watch — Atom
- Metformin Immediate-Release Tablet CI watch — JSON
- Metformin Immediate-Release Tablet alone — RSS
Cite this brief
Drug Landscape (2026). Metformin Immediate-Release Tablet — Competitive Intelligence Brief. https://druglandscape.com/ci/metformin-immediate-release-tablet. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing